Vanda Pharmaceuticals (VNDA) : Simplex Trading scooped up 33,242 additional shares in Vanda Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 40,395 shares of Vanda Pharmaceuticals which is valued at $679,848.Vanda Pharmaceuticals makes up approximately 0.09% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , First Mercantile Trust Co reduced its stake in VNDA by selling 2,440 shares or 27.54% in the most recent quarter. The Hedge Fund company now holds 6,420 shares of VNDA which is valued at $108,049. Vanda Pharmaceuticals makes up approx 0.01% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in VNDA by selling 40,975 shares or 94.17% in the most recent quarter. The Hedge Fund company now holds 2,536 shares of VNDA which is valued at $41,210.
Vanda Pharmaceuticals (VNDA) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $16.79 and reached the intraday high at $16.94. The bulls started the profit booking and pushed the shares to intraday low of $16.45. The trading session was marked by a volume range of 6,46,690 shares exchanging hands. The 52-week high of the shares is $18 and the 52-week low is $6.9099. The market cap of the company stands at $728 M and there are 4,32,84,259 shares in public circulation.
On the company’s financial health, Vanda Pharmaceuticals reported $0.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.23 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $-0.22. The company had revenue of $36.02 million for the quarter, compared to analysts expectations of $35.78 million. The company’s revenue was up 30.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.13 EPS.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon) Fanapt (iloperidone) Tradipitant (VLY-686) Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.